TRACON Pharmaceuticals Reports Granting of Inducement Award
In connection with the appointment of
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
|Company Contact:||Investor Contact:|
|Patricia Bitar||Andrew McDonald|
|Chief Financial Officer||LifeSci Advisors LLC|
|(858) 550-0780 ext. 223||646-597-6987|
Source: TRACON Pharmaceuticals, Inc.